Loading the security overview…
Where the tokens are
| Quarter | EPS | EPS vs year ago | Revenue | Revenue vs year ago |
|---|---|---|---|---|
| Q2 FY16ended Jun 30, 2016 | $0.75 | +0.0% | $12.68B | −1.7% |
| Q1 FY16ended Mar 31, 2016 | $0.84 | −84.2% | $11.81B | −3.2% |
| Q4 FY15ended Dec 31, 2015 | $0.45 | −26.2% | $12.80B | −4.1% |
| Q3 FY15ended Sep 30, 2015 | $0.77 | −41.2% | $12.49B | −6.1% |
| Q2 FY15ended Jun 30, 2015 | $0.75 | −27.2% | $12.90B | −7.5% |
| Q1 FY15ended Mar 31, 2015 | $5.32 | +347.1% | $12.20B | −6.4% |
| Q4 FY14ended Dec 31, 2014 | $0.61 | −25.6% | $13.35B | −2.0% |
| Q3 FY14ended Sep 30, 2014 | $1.31 | +45.6% | $13.30B | +3.1% |
| Q2 FY14ended Jun 30, 2014 | $1.03 | — | $13.95B | — |
| Q1 FY14ended Mar 31, 2014 |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss.
Figures describe Novartis AG shares, not any token. From Massive's standardised financials and the earnings calendar.
| $1.19 |
| — |
| $13.03B |
| — |
| Q4 FY13ended Dec 31, 2013 | $0.82 | — | $13.63B | — |
| Q3 FY13ended Sep 30, 2013 | $0.90 | — | $12.91B | — |